Article
Comparison of standard mismatch repair deficiency and microsatellite instability tests in a large cancer series
13 Feb 2024
Abstract excerpt
BACKGROUND: The tumor-agnostic indication of immune checkpoint inhibitors to treat cancers with mismatch repair deficiency (dMMR)/microsatellite instability (MSI) increased the demand for such tests beyond Lynch syndrome. International guideline recommendations accept immunohistochemistry (IHC) for dMMR or molecular techniques (PCR or NGS) for MSI status determinations considering the two tests are equal,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
